Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginFCF Payout RatioGross MarginInventory AverageInvested CapitalMarket CapitalizationNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Ani Pharmaceuticals (ANIP) Debt to Equity: 2011-2024

Historic Debt to Equity for Ani Pharmaceuticals (ANIP) over the last 11 years, with Dec 2024 value amounting to $0.79.

  • Ani Pharmaceuticals' Debt to Equity fell 1.25% to $0.62 in Q3 2025 from the same period last year, while for Sep 2025 it was $0.62, marking a year-over-year decrease of 1.25%. This contributed to the annual value of $0.79 for FY2024, which is 36.44% up from last year.
  • Latest data reveals that Ani Pharmaceuticals reported Debt to Equity of $0.79 as of FY2024, which was up 36.44% from $0.58 recorded in FY2023.
  • Ani Pharmaceuticals' 5-year Debt to Equity high stood at $0.87 for FY2020, and its period low was $0.58 during FY2023.
  • Its 3-year average for Debt to Equity is $0.69, with a median of $0.71 in 2022.
  • In the last 5 years, Ani Pharmaceuticals' Debt to Equity declined by 18.54% in 2023 and then skyrocketed by 36.44% in 2024.
  • Ani Pharmaceuticals' Debt to Equity (Yearly) stood at $0.87 in 2020, then decreased by 14.47% to $0.74 in 2021, then dropped by 4.26% to $0.71 in 2022, then declined by 18.54% to $0.58 in 2023, then spiked by 36.44% to $0.79 in 2024.